text: In the future, radioligand therapy may expand to include more α-emitter based treatments. Currently, β radioligand therapies are more commonly used in oncology. Clinical trials of α-emitters are underway due to their higher potency and ability to induce double-strand DNA breaks. There are multiple Actinium-225 based PSMA studies that will be launched in 2024. If these prove successful, there is potential for further studies and clinical trials to be done using α-emitters. Additionally, there is potential for the future use of radioligand therapy in patients with malignant brain tumors. Finally, there have been recent developments in diagnostic tracers using radioligands, as well as with radioligand-based imaging techniques and in the field of theranostics.